## **OPTIMA HEALTH PLAN**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

**<u>Drug Requested</u>**: **Myalept**<sup>®</sup> (metreleptin)

DRU	GΙ	NF	TORMATION: Complete all information be	elow or authorization may be delayed.
Drug F	orı	m/S	Strength:	
Dosing	Sc	hed	lule:	Length of Therapy:
Diagno	sis	:_		ICD Code, if applicable:
each lir	ne c	hec		All criteria must be met for approval. To support iagnostics, and/or chart notes, must be provided
			ON AND CONTINUATION OF TREA qualify.	ATMENT – All boxes below must be
			er has a leptin deficiency as defined as (a copy red for approval):	of fasting laboratory leptin assay results is
		<4	.0 ng/mL fasting leptin for females	
		<3	.0 ng/mL fasting leptin for males	
	Me	mb	er has a diagnosis of (choose indication):	
		Ac	equired generalized lipodystrophy	
		Co	ongenital generalized lipodystrophy	
	Me	mb	er has a concurrent condition of:	
		Di	abetes mellitus or insulin resistance and failed 3	30-day trial of (submit chart notes):
			Metformin, total daily dose of:	
			AND	
			High-dose insulin or insulin pump	
		Ну	pertriglyceridemia and failed 30-day trial of (su	ubmit chart notes):
			Low-fat diet and/or dietary restrictions	
			AND	
			Fenofibrate or fenofibrate derivative	
			OR	
			Niacin or omega-3 fatty acid	
			(Continued on ne	xt page)

UK
Atorvastatin, simvastatin, pravastatin, rosuvastatin
OR
Other therapy of (please specify):

INITIATION OF TREAT (submit all labs)	CMENT	<u>REAUTHORIZATION</u> (submit all labs)		
HbA1c%		HbA1c%		
Fasting glucose	mg/dL	Fasting glucose mg/dI		
Triglyceride	mg/dL	Triglyceride mg/dL		
Patient weight	kg	Patient weightkg		
		Has member experienced clinical improvem metabolic stabilization while using this med (submit chart notes to verify response)  Yes No		

If approved, response to initial treatment will be <u>assessed after 4 months</u>, then <u>quarterly</u> <u>reassessment</u> will be required for continued approval.

Modication	hoing provi	dod by	Specialty	Dharmaay	<b>PropriumRx</b>
Medication	Deing Drovi	laea by	Specialty	Pharmacy -	Propriumex

\*\* Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*

Member Name:			
Member Optima #:	Date of Birth:		
Prescriber Name:			
Prescriber Signature:			
Office Contact Name:			
Phone Number:	Fax Number:		
DEA OR NPI #•			

\*Approved by Pharmacy and Therapeutics Committee: 4/16/2015

REVISED/UPDATED: 5/27/2015; 12/28/2015; 9/22/2016; 12/21/2016; 8/4/2017; (Reformatted) 9/6/2019